io digital currency, Knowledge

The ethylene plant of ExxonMobil Huizhou Ethylene Phase I Project entered the commissioning stage, and ExxonMobil China announced that in December 2024, the 1.6 million tons ethylene plant of ExxonMobil Huizhou Ethylene Phase I Project was handed over to China and entered the commissioning stage in an all-round way. ExxonMobil Huizhou Ethylene Project is located in Huizhou Daya Bay Petrochemical Park. The first phase of the project mainly includes ethylene plants, high-end polyethylene and polypropylene production plants in the middle and lower reaches, and supporting utilities, docks, storage and transportation and environmental protection facilities.Xiong 'an Center of Beijing-Tianjin-Hebei National Technology Innovation Center officially started operation. On December 12th, Xiong 'an Center of Beijing-Tianjin-Hebei National Technology Innovation Center officially started operation, including the cooperation project of Xiong 'an Medical and Industrial Cross Transformation Research Institute of Peking University People's Hospital and the fourth generation semiconductor material doped AlN epitaxial wafer, and many independent innovative projects landed in xiong'an new area. As a national innovation platform, Xiong 'an Center will focus on key tasks such as building a first-class innovation platform, forming a composite innovation team, and improving the innovation and entrepreneurship ecology, and strive to create an important source of independent innovation and original innovation. (CCTV News)In 2024, the qualification examination and approval of the first batch of new materials insurance compensation was started, and the Ministry of Industry and Information Technology recently issued a notice to organize the qualification examination and approval of the first batch of new materials insurance compensation in 2024. It is clear that the enterprise applying for qualification should be an enterprise that produces and manufactures the products listed in the Catalogue for the Demonstration and Guidance of the First Application of Key New Materials (2024 Edition). It belongs to an independent legal person registered in People's Republic of China (PRC), has strong design and development, manufacturing and industrialization capabilities, has a relatively complete team of professional technicians, and has mastered the core technology and intellectual property rights of this product development. The qualification examination and approval procedures need to go through three steps: enterprise declaration, review by local industrial and information authorities or recommended units such as the central enterprise group, and expert review organized by the Ministry of Industry and Information Technology. After review, the product compensation qualification is determined, and the amount of subsidy funds is approved according to a certain proportion of the product value, and the effective period is no more than 3 years.

Wang Xiaochuan Baichuan Intelligent has set up a technology company in Ningbo with a number of AI businesses. According to enterprise investigation, recently, Ningbo Baichuan Ronghui Technology Co., Ltd. was established with Wang Xiaochuan as the legal representative and a registered capital of 70 million US dollars. Its business scope includes artificial intelligence dual-creation service platform, artificial intelligence theory and algorithm software development, artificial intelligence basic software development, artificial intelligence general application system, artificial intelligence public data platform and artificial intelligence public service platform technical consulting service. Equity penetration shows that the company is wholly owned by BAICHUAN AI (HK) LIMITED.Treasury futures rose by 0.30%, the 30-year main contract rose by 0.30%, and the 30-year main contract rose by 0.30%, a record high. The 10-year main contract rose by 0.12%, the 5-year main contract rose by 0.05% and the 2-year main contract rose by 0.02%.The next "explosion point" of biomedicine may appear in Shenzhen. "China's pharmaceutical innovation ranks first in the second echelon in the world in terms of the quantitative indicators of R&D pipelines and listed new drugs." A few days ago, Song Ruilin, executive president of China Pharmaceutical Innovation Promotion Association, held the "Star of the Bay Area" biomedical source innovation conference in Shenzhen, and believed that China's pharmaceutical research and industrial development were entering a new stage of innovation. Chen Qiyu, vice president of China Pharmaceutical Innovation Promotion Association and executive director and co-CEO of Fosun International, said that Shenzhen has great advantages and development momentum in linking Greater Bay Area's urban development and AI technology. By leveraging the resources in the Bay Area and making good use of these advantages, it is possible to find a new fulcrum in the future biomedical R&D innovation track, and the next "explosion point" of biomedicine is likely to appear in Shenzhen.

The National Green Development Fund and other companies have established ecological restoration production and investment partnerships. According to the enterprise survey APP, recently, Jiangxi Green Gold Ecological Restoration Industry Investment Partnership (Limited Partnership) was established with a capital contribution of 1 billion yuan, and its business scope includes: engaging in equity investment, investment management, asset management and other activities with private equity funds. Enterprise investigation shows that the company is jointly owned by National Green Development Fund Co., Ltd. and Jiangxi Jinkong Investment Group Co., Ltd.The securities sector fluctuated and strengthened, and the securities sector fluctuated and strengthened. Guosheng Financial Holdings had three consecutive boards, Guolian Securities rose more than 8%, and Harbin Investment Co., Ltd., Huaxin Co., Ltd., Cinda Securities and Southwest Securities followed suit.The trading of traditional Chinese medicine has increased the daily limit of Panlong Pharmaceutical, the trading of traditional Chinese medicine has increased, Panlong Pharmaceutical has increased its daily limit, Xiangxue Pharmaceutical has increased by over 9%, and Kunyao Group, Weikang Pharmaceutical, Huasen Pharmaceutical and Xinguang Pharmaceutical have followed suit.